Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT01597388
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT01597193
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC., Nashville, Tennessee, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT01560416
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸New Hampshire Oncology and Hematology, P.A., Concord, New Hampshire, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
- Conditions
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2021-01-08
- Target Recruit Count
- 379
- Registration Number
- NCT01556191
- Locations
- 🇫🇷
Clinique de l'Europe, Amiens, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 97
- Registration Number
- NCT01528345
- Locations
- 🇺🇸
City of Hope National Medical Center COH 3, Duarte, California, United States
🇺🇸University of California San Diego - Moores Cancer Center Moores UCSD Cancer Ctr. SC-1, La Jolla, California, United States
🇺🇸ProHealth Care, Lake Success, New York, United States
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
- Conditions
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Isabel Blancas
- Target Recruit Count
- 272
- Registration Number
- NCT01509625
- Locations
- 🇪🇸
Hospital SAS Jeréz de la Frontera, Jeréz de la Frontera, Spain
🇪🇸Hospital Carlos Hayas, Málaga, Spain
🇪🇸Hospital Torrecardenas Almería, Almería, Spain
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT01441947
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT01437566
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 140
- Registration Number
- NCT01399086
- Locations
- 🇬🇷
Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 225
- Registration Number
- NCT01394016
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.